Applicability of botulinum toxin type A in paediatric neurogenic bladder management
暂无分享,去创建一个
[1] I. bonan,et al. Outcomes of intra‐detrusor injections of botulinum toxin in patients with spina bifida: A systematic review , 2016, Neurourology and urodynamics.
[2] P. Tyagi,et al. Urodynamic and Immunohistochemical Evaluation of Intravesical Botulinum Toxin A Delivery Using Low Energy Shock Waves. , 2016, The Journal of urology.
[3] J. Abbott,et al. Ten years of experience with intravesical and intrasphincteric onabotulinumtoxinA in children. , 2016, Journal of pediatric urology.
[4] P. Reddy,et al. Botulinum toxin injection in the pediatric population with medically refractory neuropathic bladder. , 2016, Journal of pediatric urology.
[5] E. Shreck,et al. Indications for Augmentation Cystoplasty in the Era of OnabotulinumtoxinA , 2016, Current Urology Reports.
[6] M. Chancellor,et al. Bladder Uptake of Liposomes after Intravesical Administration Occurs by Endocytosis , 2015, PloS one.
[7] I. Yağmur,et al. Botulinum injection is useless on fibrotic neuropathic bladders. , 2015, Journal of pediatric urology.
[8] D. Gultyaev,et al. Cost-Effectiveness Analysis of OnabotulinumtoxinA (BOTOX®) for the Management of Urinary Incontinence in Adults with Neurogenic Detrusor Overactivity: A UK Perspective , 2014, PharmacoEconomics.
[9] M. Chancellor,et al. Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial. , 2014, The Journal of urology.
[10] S. Taskinen,et al. Effect of onabotulinumtoxinA treatment on symptoms and urodynamic findings in pediatric neurogenic bladder. , 2014, Journal of pediatric urology.
[11] R. Dmochowski,et al. Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States. , 2013, Clinical therapeutics.
[12] Ş. Çetinel,et al. Intradetrusor botulinum neurotoxin A (BoNT‐A) injections decrease bladder fibrosis secondary to partial urethral obstruction in the male rat model , 2012, Neurourology and urodynamics.
[13] S. Tuncer,et al. The effect of surgical and chemical denervation on ischaemia/reperfusion injury of skeletal muscle. , 2012, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.
[14] M. Yeh,et al. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy , 2011, International journal of nanomedicine.
[15] A. Amelink,et al. Changes in bladder wall blood oxygen saturation in the overactive obstructed bladder. , 2011, The Journal of urology.
[16] H. Ahmadi,et al. Intravesical electromotive botulinum toxin type A administration: part I--Experimental study. , 2011, Urology.
[17] Y. Liu,et al. Botulinum Toxin Type A Inhibits Connective Tissue Growth Factor Expression in Fibroblasts Derived From Hypertrophic Scar , 2011, Aesthetic Plastic Surgery.
[18] S. Bazargan-Hejazi,et al. Intravesical electromotive botulinum toxin type A administration--part II: Clinical application. , 2011, Urology.
[19] J. Krhut,et al. Intravesical instillation of botulinum toxin A: an in vivo murine study and pilot clinical trial , 2011, International Urology and Nephrology.
[20] R. Banerjee,et al. Intravesical drug delivery: Challenges, current status, opportunities and novel strategies. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[21] P. Habibollahi,et al. Intravesical injections of botulinum toxin type A for management of neuropathic bladder: a comparison of two methods. , 2010, Urology.
[22] J. Frevert. Content of Botulinum Neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture® , 2010, Drugs in R&D.
[23] Byung-Joo Lee,et al. Effect of Botulinum Toxin Type A on a Rat Surgical Wound Model , 2009, Clinical and experimental otorhinolaryngology.
[24] M. Chancellor,et al. New frontiers in intravesical therapies and drug delivery. , 2006, European urology.
[25] P. Dik,et al. Early start to therapy preserves kidney function in spina bifida patients. , 2006 .
[26] I. Tuğlu,et al. The effects of botulinum-A toxin on bladder function and histology in spinal cord injured rats: is there any difference between early and late application? , 2005, The Journal of urology.
[27] G. Somogyi,et al. In vivo effects of botulinum toxin A on visceral sensory function in chronic spinal cord-injured rats. , 2005, Urology.
[28] N. Kinukawa,et al. Risk factors for febrile urinary tract infection in children with myelodysplasia treated by clean intermittent catheterization , 2004, International journal of urology : official journal of the Japanese Urological Association.
[29] A. Brading,et al. Effects of metabolic stress and ischaemia on the bladder, and the relationship with bladder overactivity , 2004, Scandinavian journal of urology and nephrology. Supplementum.
[30] T. Michael,et al. Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. , 2002, Urology.
[31] T. Schlager,et al. Effect of a single-use sterile catheter for each void on the frequency of bacteriuria in children with neurogenic bladder on intermittent catheterization for bladder emptying. , 2001, Pediatrics.
[32] D. Schmid,et al. Treatment of neurogenic incontinence with botulinum toxin A. , 2000, The New England journal of medicine.
[33] S. Bauer,et al. Prognostic value of urodynamic testing in myelodysplastic patients. , 1981, The Journal of urology.
[34] J. Lorber,et al. Results of Treatment of Myelomeningocele , 1971, Developmental medicine and child neurology.